Cambridge Epigenetix Ltd
Epigenetic modifications occur early in disease development. Cambridge Epigenetix is utilising its disruptive and highly sensitive 5hmC profiling platform, in combination with minimally-invasive techniques such as liquid biopsy, to provide affordable and accurate analysis of clinical samples to facilitate early detection of cancer and a number of other important diseases with unmet diagnostic needs.
Spun-out of the University of Cambridge in 2012, the Company was founded by Professor Sir Shankar Balasubramanian (co-inventor of Solexa sequencing) and Dr Bobby Yerramilli-Rao to commercialise its founding technology, oxidative bisulfite sequencing (oxBS-Seq), which enables users to quantify, and discriminate between, functionally-distinct DNA modifications – impossible with traditional bisulfite methods.
A privately held company headquartered in Cambridge, UK, Cambridge Epigenetix is supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures, Ahren Innovation Capital and the University of Cambridge.
For more information, visit www.cambridge-epigenetix.com